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Background: Vitamin D is an important mediator of  calcium metabolism. It has 
also been implicated as a potential contributor to the pathophysiology of  various 
extra-skeletal conditions, consisting hypertension, renal disease, and insulin 
resistance. 
Objectives: The primary objective of  this study was to determine whether oral 
vitamin D (cholecalciferol) supplementation can lead to improvement of  blood 
pressure in type 2 diabetes patients. 
Patients and Methods: This study was a double blind clinical trial conducted on 60 
type 2 diabetes mellitus patients. Exclusion criteria were taking calcium, vitamin 
D supplements or any drugs effecting calcium and vitamin D metabolism in the 
past 6 months.  Patients were administered weekly vitamin D supplementation 
(50000 units) for 12 weeks. Serum 25-Hydroxy vitamin D [25(OH)D] level was 
measured with ELISA method.
Results: Five patients (8.3%) had vitamin D deficiency, 27 (45%) had insufficient 
levels of  vitamin D and in 28 (45%) patients vitamin D level was within normal 
limits. The means of  systolic blood pressure (BP) and diastolic BP in patients 
before intervention were 121 and 80.5 mmHg; after intervention they were 110 
and 76.3 mmHg, respectively. After intervention, systolic and diastolic blood 
pressure levels were significantly less than control group (p< 0.01).
Conclusions: In this study we found that weekly vitamin D supplementation 
(cholecalciferol; 50,000 units for 12 weeks) had beneficial effect on the level of 
blood pressure in type 2 diabetic patients. Thus, oral vitamin D may help in 
improvement of  hypertension in these patients.
Implication for health policy/practice/research/medical education:
In this study we found that weekly vitamin D supplementation (cholecalciferol; 50,000 units for 12 weeks) 
had beneficial effect on level of  blood pressure in type 2 diabetic patients. Thus, oral vitamin D may help in 
improvement of  hypertension in these patients.
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1. Introduction
Vitamin D is an important mediator of  calci-
um metabolism. It has also been implicated as a 
potential contributor to the pathophysiology of 
various extra-skeletal conditions, consisting hy-
pertension, renal disease and insulin resistance 
(1). Studies suggest that low 25-hyroxyvitamin D 
is associated with cardiovascular disease, microal-
buminuria, inflammation, diabetes and metabolic 
syndrome. Studies have shown the worldwide de-
ficiency of  vitamin D, however, deficiency of  this 
vitamin has been found a global pandemic for a 
while and the level of  attention given by the sci-
entific and clinical community was only recently 
stimulated, basically due to the pleiotropic effects 
of  this hormone outside the skeletal system (1-3).
Animal studies suggest that low serum 25-hy-
droxyvitamin D (25[OH]D) may impair insulin 
synthesis and secretion, and might be involved in 
the pathogenesis of  diabetes (2,3). On the other 
hand, the global prevalence of  type 2 diabetes is 
growing in parallel to vitamin D deficiency and 
diabetic kidney disease is a major risk for end-
stage kidney disease. 
Many complex factors relate to the progression 
of  diabetic kidney disease (1-4). Recently much 
attention has been directed toward the vitamin D 
supplementation in diabetic patients while vari-
ous epidemiological studies have shown associa-
tions between low concentrations of  25-hydroxy 
vitamin D and the incidence of  diabetes and its 
complications (2-4).
Dietary vitamin D supplementation is associat-
ed with reduced risk of  type 1 diabetes in ani-
mals (3,4). Observational studies have shown 
higher blood pressure trends in winter months, 
proposing that low ultraviolet radiation and thus 
decreased capacity for cutaneous vitamin D syn-
thesis are associated with hypertension.
2. Objectives
The primary objective of  this study was to de-
termine whether oral vitamin D (cholecalciferol) 
supplementation could lead to improvement of 
blood pressure in type 2 diabetic patients. 
3. Patients and Methods 
3.1. Study population
This study was a randomized, double-blind, pla-
cebo controlled clinical trial on 60 patients with 
the diagnosis of  type 2 diabetes referred to en-
docrinology clinic of  Shahrekord University of 
Medical Sciences in 2011. The patients were al-
located into two equal groups of  30 by comput-
er-generated randomly permutated codes (pre-
pared by WHO/Geneva). The inclusion criteria 
were definite diagnosis of  type 2 diabetes accord-
ing to standard criteria, no kidney or liver disease 
or any other chronic illness according to the his-
tory and physical examinations. Exclusion criteria 
were taking oral calcium, vitamin D supplements 
or any drugs effecting calcium or vitamin D me-
tabolism, in the past six months.
3.2. Laboratory tests
First, the blood level of  25-Hydroxy vitamin D 
[25(OH)D] was measured in all the patients. One 
group received oral vitamin D (cholecalciferol; 
50000 units/week) for 12 weeks, while the other 
group received placebo for the same period of 
time. In all patients, fasting blood sugar (FBS), 
blood sugar (BS), 2 hour postprandial blood sug-
ar (2-hpp) and HbA1c were measured before 
and after drug therapy. Plasma 25(OH)D was 
measured with ELISA method by Stat fax 2100 
produced by Awareness Company (The Unit-
ed States). HbA1c was measured using column 
chromatography method with Nyco card read-
er II made in Norway. FBS, 2-hpp and BS were 
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measured using spectrophotometer by Erba-XL 
300 made in Germany.
3.3. Ethical issues
The research followed the tenets of  the Declara-
tion of  Helsinki. Written informed consent was 
obtained from all patients. This study was ap-
proved by Ethical Committee of  Shahrekord Uni-
versity of  Medical Science. This study was regis-
tered in Iranian Registry of  Clinical Trials (IRCT) 
and achieved the code of  IRCT201011185191N6, 
too.
3.4. Statistical analysis
The data was analyzed with Stata software (Stata 
Corp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: Stata Corp LP) using stu-
dent t-test, paired t-test, Pearson correlation and 
Chi square tests. P values of  less than 0.05 was 
assumed to be significant (p<0.05).
4. Results
A total number of  60 type 2 diabetic patients 
were randomly assigned into two groups of  inter-
vention and control, each group consisting of  30 
patients. The intervention group received vitamin 
D and the control group received placebo. The 
age of  the patients ranged from 34 to 76 with the 
mean (SD) age of  55 (10.7) years. There was no 
significant difference for age between groups (p= 
0.88). Seventeen patients (28.3%) were male. The 
female to male ratio was not statistically signifi-
cant (p= 0.58). Table 1 demonstrates the labora-
tory parameters of  both groups before and after 
the intervention. 
Means of  systolic blood pressure (BP) and dia-
stolic BP in patients before intervention were 
121 and 80.5 mmHg; after intervention they 
changed to 110 and 76.3 mmHg, respectively. 
After intervention, 25 (OH)D level in interven-
tional group was higher significantly compared 
to control group. Table 2 demonstrates that after 
intervention, systolic and diastolic blood pressure 
levels were significantly less than control group 
(p<0.01).
5. Discussion
The extraskeletal effects of  vitamin D have 
attracted significant interest. There is an 
abundance of  human clinical investigations 
examining the potential relation between levels 
of  vitamin D metabolites with glycemic control 
and the incidence of  diabetes. In various small 
supplementation investigations, interventions to 
increase 25-hydroxyvitamin D has been found 
to reduce blood pressure in populations at risk 
of  cardiovascular disease (2-5). There is also 
some evidences that vitamin D supplementation 
increases pancreatic insulin release and improves, 
impaired glucose tolerance and insulin resistance 
in patients with type 2 diabetes. In our study, we 
found that a short course of  vitamin D therapy, 
Table 1. Mean (SD) of  25(OH) D (nmol/l) in interventional, control and total groups.
Group
Intervention Group Control Group Comparison Between Group P value*
Before
Mean(SD)
After
Mean(SD)
P value
Before
Mean(SD)
After
Mean(SD)
P 
value
Interventional Control
Male 82.5(49) 167.8(32) 0.001* 93.3(67) 94.5(55) 0.83 0.002* 0.971
Female 84.6(54) 162.2(67) 0.001* 109.5(64) 122.2(103) 0.4 0.003* 0.619
Total 83.9(52) 164(57) 0.001* 105.7(64) 115.8(94) 0.39 0.001* 0.632
*P <0.05 comparing the data of  each group before and after intervention
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Table 2. Mean (SD) of  systolic (SYS) and diastolic (DIAS) BP and body mass index in sex groups and total groups
Time of 
measurement Intervention Group Control Group
Comparison Between 
Group P value*
Group
Before
Mean(SD)
After
Mean(SD)
P value
Before
Mean(SD)
After
Mean(SD)
P 
value
Interventional Control
SYS BP
Male 120(13) 113(9.7) 0.006* 117(14) 114(5) 0.522 0.012* 0.05
Female 121.5(13) 109.5(9) 0.001* 119.3(10) 114.7(10) 0.094 0.001* 0.085
Total 121(13)  110(9) 0.001* 118.8(11) 114.6(9) 0.06 0.001* 0.09
DIASBP
Male 79.5(9) 77(10) 0.32 80(8) 77(4) 0.35 0.35 0.35
Female 81(7) 76(6) 0.007* 80.4(7) 79(4) 0.62 0.01* 0.76
Total 80.5(8) 76.3(7) 0.046* 80.3(7) 79(4) 0.38 0.01* 0.58
BMI 
(kg/m2)
Male 27.4(4) 27(4) 0.153 27.4(4) 27(4) 0.153 0.53 0.15
Female 30.2(4) 30.3(4) 0.731 30.2(4) 30.3(4) 0.731 0.73 0.73
Total 29.31(4.4) 29.2(4) 0.63 28.8 (4.5) 28.7 (5.2) 0.48 0.73 0.68
*P <0.05 comparing the data of  each group before and after intervention
improved the blood pressure in type 2 diabetic 
patients. Indeed, vitamin D metabolites have 
been related with the regulation of  blood pressure 
(3-8). Interestingly observational reports have 
observed higher blood pressure trends in winter 
months, proposing that low ultraviolet radiation 
and thus decreased capacity for cutaneous 
vitamin D synthesis are connected with high 
blood pressure (2-8). The most noteworthy 
mechanism associating vitamin D with high 
blood pressure is its role as a negative regulator 
of  the renin-angiotensin system, other notable 
hypotheses have suggested that vitamin D affects 
vascular endothelial function or vascular smooth 
muscle intracellular calcium concentrations (4-
8). Study of  Gupta et al, showed that vitamin 
D level has inverse correlation with circulating 
renin and angiotensin II, suggesting a mechanism 
for elevation of  blood pressure. Additionally, 
dietary supplementation with vitamin D appears 
to reduce blood glucose and blood pressure. It is 
probable that low serum vitamin D levels elevate 
the risk for early-stage diabetes and high blood 
pressure (9).
6.  Conclusions
In this study we found that weekly vitamin D 
supplementation (cholecalciferol; 50,000 units 
for 12 weeks) had beneficial effect on the level of 
blood pressure in type 2 diabetic patients. Thus, 
oral vitamin D may help in improvement of  hy-
pertension in these patients.
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